First Time Loading...

Biohaven Pharmaceutical Holding Company Ltd
NYSE:BHVN

Watchlist Manager
Biohaven Pharmaceutical Holding Company Ltd Logo
Biohaven Pharmaceutical Holding Company Ltd
NYSE:BHVN
Watchlist
Price: 54.69 USD -4.09% Market Closed
Updated: Mar 29, 2024

Intrinsic Value

Biohaven Pharmaceutical Holding Co. Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of late-stage product candidates targeting neurological diseases,... [ Read More ]

There is not enough data to reliably calculate the intrinsic value of BHVN.

Key Points:
BHVN Intrinsic Value
Base Case
Not Available
Base Case Scenario

Fundamental Analysis

How can I assist you today?

Provide an overview
of Biohaven Pharmaceutical Holding Company Ltd's business.

What risks and challenges
does Biohaven Pharmaceutical Holding Company Ltd face in the near future?

Summarize the latest earnings report
of Biohaven Pharmaceutical Holding Company Ltd.

Provide P/E
for Biohaven Pharmaceutical Holding Company Ltd and its competitors.

Financials

Balance Sheet Decomposition
Biohaven Pharmaceutical Holding Company Ltd

Current Assets 442.4m
Cash & Short-Term Investments 381.8m
Receivables 13.6m
Other Current Assets 47m
Non-Current Assets 70.8m
PP&E 48.6m
Intangibles 19.8m
Other Non-Current Assets 2.4m
Current Liabilities 55.4m
Accounts Payable 15.6m
Accrued Liabilities 39.8m
Non-Current Liabilities 29.8m
Other Non-Current Liabilities 29.8m
Efficiency

Earnings Waterfall
Biohaven Pharmaceutical Holding Company Ltd

Revenue
0 USD
Operating Expenses
-436.1m USD
Operating Income
-436.1m USD
Other Expenses
27.9m USD
Net Income
-408.2m USD

Free Cash Flow Analysis
Biohaven Pharmaceutical Holding Company Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

BHVN Profitability Score
Profitability Due Diligence

Biohaven Pharmaceutical Holding Company Ltd's profitability score is 27/100. The higher the profitability score, the more profitable the company is.

27/100
Profitability
Score

Biohaven Pharmaceutical Holding Company Ltd's profitability score is 27/100. The higher the profitability score, the more profitable the company is.

BHVN Solvency Score
Solvency Due Diligence

Biohaven Pharmaceutical Holding Company Ltd's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Low D/E
81/100
Solvency
Score

Biohaven Pharmaceutical Holding Company Ltd's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

BHVN Price Targets Summary
Biohaven Pharmaceutical Holding Company Ltd

Wall Street analysts forecast BHVN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for BHVN is 60.69 USD with a low forecast of 55.55 USD and a high forecast of 69.3 USD.

Lowest
Price Target
55.55 USD
2% Upside
Average
Price Target
60.69 USD
11% Upside
Highest
Price Target
69.3 USD
27% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

BHVN Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

BHVN Price
Biohaven Pharmaceutical Holding Company Ltd

1M 1M
+14%
6M 6M
+110%
1Y 1Y
+290%
3Y 3Y
+649%
5Y 5Y
+649%
10Y 10Y
+649%
Annual Price Range
54.69
52w Low
12.64
52w High
59.75
Price Metrics
Average Annual Return 84.93%
Standard Deviation of Annual Returns
N/A
Max Drawdown -25%
Shares Statistics
Market Capitalization 4.4B USD
Shares Outstanding 80 230 000
Percentage of Shares Shorted 10.8%

BHVN Return Decomposition
Main factors of price return

What is price return decomposition?

BHVN News

Other Videos

Last Important Events
Biohaven Pharmaceutical Holding Company Ltd

Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.

All
Positive
Negative

Sentiment Analysis
Biohaven Pharmaceutical Holding Company Ltd

Today
Last 7 Days 7D
Last 30 Days 30D
Last 90 Days 90D

Company Profile

Biohaven Pharmaceutical Holding Company Ltd Logo
Biohaven Pharmaceutical Holding Company Ltd

Country

United States of America

Industry

Biotechnology

Market Cap

4.4B USD

Dividend Yield

0%

Description

Biohaven Pharmaceutical Holding Co. Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of late-stage product candidates targeting neurological diseases, including rare disorders. The company is headquartered in New Haven, Connecticut and currently employs 928 full-time employees. The company went IPO on 2017-05-04. The firm has a portfolio of therapies to improve the lives of patients with debilitating neurological and neuropsychiatric diseases, including rare disorders. The firm's Neuroinnovation portfolio includes NURTEC ODT (rimegepant) for the acute and preventive treatment of migraine and a pipeline of product candidates across five platforms: calcitonin gene related peptide (CGRP) receptor antagonism for the acute and preventive treatment of migraine as well as other pain-related disorders and non-migraine indications; glutamate modulation for obsessive-compulsive disorder (OCD); myeloperoxidase (MPO) inhibition for multiple system atrophy (MSA) and amyotrophic lateral sclerosis (ALS); Kv7 Ion Channel Activators (Kv7) to target indications including epilepsy, pain disorders and effective disorders; and Myostatin offers a natural protein that limits skeletal muscle growth.

Contact

CONNECTICUT
New Haven
215 Church St
+12034040410.0
http://biohavenpharma.com/

IPO

2017-05-04

Employees

928

Officers

Chairman & CEO
Dr. Vladimir Coric M.D.
Chief Financial Officer
Mr. Matthew Buten
Chief Scientific Officer
Dr. Bruce D. Car DACVP, Ph.D.
Director of Regulatory Affairs & Operations
Ms. Deb Young
VP & Chief Accounting Officer
Mr. George C. Clark
Vice President of Investor Relations
Ms. Jennifer Porcelli
Show More
General Counsel & Chief Legal Officer
Mr. Warren Volles J.D.
President, GM of Biohaven Ireland & Chief Compliance Officer
Mr. Clifford Bechtold M.S.
Senior Vice President of Clinical Operations
Ms. Kimberly Gentile
Chief Commercial Officer of Rare Diseases
Mr. John Tilton
Show Less

See Also

Discover More